An overview of newborn screening

Area of Science:

• Medical Genetics
• Public Health
• Bioethics

Background:

• Newborn screening began with phenylketonuria (PKU) and has evolved significantly.
• The adoption of tandem mass spectrometry (MS-MS) technology dramatically increased the number of detectable disorders.
• Inequities in state-specific newborn screening panels prompted calls for national standardization.

Purpose of the Study:

• To review the history and evolution of newborn screening.
• To explore the principles and criteria for adding disorders to screening panels.
• To discuss the ethical, financial, and social implications of expanding newborn screening.

Main Methods:

• Literature review of historical developments in newborn screening.
• Analysis of expert panel recommendations for standardized screening panels.
• Examination of ethical debates surrounding expanded newborn screening.

Main Results:

• The development of MS-MS technology led to a rapid increase in screened conditions.
• An expert panel recommended a standardized panel of 29 core and 25 secondary disorders.
• Expansion of testing has reignited ethical discussions on consent, participation, and cost.

Conclusions:

• Newborn screening is rapidly expanding, driven by technological advancements.
• Ethical, financial, and social factors are critical considerations in this expansion.
• Ongoing evaluation is necessary to balance benefits and challenges of widespread newborn screening.